首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1904416

帶狀皰疹疫苗市場規模、佔有率和成長分析（按產品類型、疫苗類型和地區分類）－2026-2033年產業預測

Shingles Vaccine Market Size, Share, and Growth Analysis, By Product (Shingrix, Zostavax), By Vaccine Type (Recombinant Vaccine, Live Attenuated Vaccine), By Region - Industry Forecast 2026-2033

出版日期: 2025年12月25日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，帶狀皰疹疫苗市場規模將達到 40.6 億美元，到 2025 年將達到 43.6 億美元，到 2033 年將達到 78.4 億美元，預測期（2026-2033 年）的複合年成長率為 7.6%。

帶狀皰疹疫苗市場持續擴張，主要促進因素是60歲及以上人口患帶狀皰疹的風險不斷增加，以及已開發國家醫療政策的發展。在美國，大約三分之一的人一生中會患上帶狀皰疹，因此主要國家都建議推廣接種疫苗。帶狀皰疹疫苗接種的重要性已被公認為一項重要的預防性措施。儘管重組疫苗高成本，但其創新仍在推動市場成長。監管機構建議使用欣格瑞（Shingrix）疫苗，因為它比傳統疫苗更有效，這一趨勢在包括加拿大和澳洲在內的多個國家都有體現。隨著帶狀皰疹病例老齡化成長而增加，預計疫苗需求將持續成長，這凸顯了疫苗接種在疾病預防中的重要作用。

帶狀皰疹疫苗市場促進因素

帶狀皰疹在全球日益普遍，是推動帶狀皰疹疫苗市場擴張的主要因素。隨著人口老化，罹患帶狀皰疹及其併發症的風險也相應增加。這種人口結構變化凸顯了採取有效預防措施以遏制帶狀皰疹發病率的緊迫性。因此，醫療系統和個人層面都越來越意識到接種疫苗的重要性，從而導致帶狀皰疹疫苗的需求不斷成長。這種對預防性醫療保健措施必要性的日益增強的認知和理解，在推動市場成長方面發揮關鍵作用。

限制帶狀皰疹疫苗市場的因素

帶狀皰疹疫苗市場面臨許多挑戰，阻礙了其成長潛力。儘管強烈建議接種疫苗，但各地的接種率仍然低得令人失望。這種猶豫不決源於多種因素，包括公眾對疫苗益處的認知不足、對疫苗必要性的懷疑以及對可能副作用的擔憂。這些障礙不僅阻礙了人們接種疫苗，也導致市場成長停滯，從而妨礙了有效控制帶狀皰疹傳播的努力，並限制了受影響地區公共衛生狀況的整體改善。

帶狀皰疹疫苗市場趨勢

帶狀皰疹疫苗市場呈現顯著上升趨勢，主要受帶狀皰疹感染病例增加（尤其是在老年人中）的推動。隨著人們對帶狀皰疹潛在併發症的認知不斷提高，醫療保健提供者和患者越來越重視接種疫苗作為預防措施。疫苗有效性和安全性的提升進一步推動了需求的成長。此外，旨在教育大眾了解疫苗接種重要性的公共衛生宣傳活動也促進了市場成長。因此，在人口結構變化和對預防性醫療保健日益重視的推動下，帶狀皰疹疫苗市場預計將迎來強勁成長。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2021-2023年營收年比比較

主要企業簡介

GlaxoSmithKline（GSK）
Merck & Co., Inc.
Pfizer Inc.
BioNTech SE
SK bioscience
GeneOne Life Science
Curevo Inc.
Vaccitech
Jiangsu Recbio Technology Co., Ltd.
Changchun BCHT Biotechnology Co.

結論與建議

簡介目錄

Product Code: SQMIG35I2264

Shingles Vaccine Market size was valued at USD 4.06 Billion in 2024 and is poised to grow from USD 4.36 Billion in 2025 to USD 7.84 Billion by 2033, growing at a CAGR of 7.6% during the forecast period (2026-2033).

The shingles vaccine market is expanding, significantly driven by the increased risk of shingles in individuals aged 60 and above and advancements in healthcare policies across developed nations. Roughly one in three people in the U.S. will encounter shingles in their lifetime, with major countries endorsing vaccination initiatives. The importance of shingles vaccination has been recognized as essential preventive care. Innovations in recombinant vaccines are enhancing market growth, despite their higher costs. Regulatory bodies favor Shingrix over previous options due to its superior efficacy, a trend mirrored in various countries such as Canada and Australia. As cases of herpes zoster rise with age, the demand for vaccines is set to increase, emphasizing the critical role vaccination plays in disease prevention.

Top-down and bottom-up approaches were used to estimate and validate the size of the Shingles Vaccine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Shingles Vaccine Market Segments Analysis

Global Shingles Vaccine Market is segmented by product, vaccine type and region. Based on product, the market is segmented into shingrix, zostavax and skyzoster. Based on vaccine type, the market is segmented into recombinant vaccine and live attenuated vaccine. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Shingles Vaccine Market

The increasing global prevalence of shingles serves as a major catalyst for the expansion of the shingles vaccine market. As populations age, there is a corresponding rise in the risk of developing shingles and experiencing complications associated with the condition. This demographic shift highlights the urgent need for effective preventive solutions to combat the incidence of shingles. Consequently, healthcare systems and individuals are becoming more aware of the importance of vaccination, leading to greater demand for shingles vaccines. This growing awareness and recognition of the need for preventive healthcare measures play a crucial role in driving market growth.

Restraints in the Shingles Vaccine Market

The Shingles Vaccine market experiences notable challenges that hinder its growth potential. Despite the robust endorsements for vaccination, the uptake in various regions continues to be disappointingly low. This hesitance can be attributed to several factors, including insufficient public awareness regarding the benefits of the vaccine, skepticism about its necessity, and apprehensions related to possible side effects. These barriers not only deter individuals from getting vaccinated but also contribute to a stagnation in market expansion, impeding efforts to combat the prevalence of shingles effectively and limiting overall public health improvements in affected areas.

Market Trends of the Shingles Vaccine Market

The shingles vaccine market is experiencing a significant upward trend, primarily fueled by the rising incidence of shingles infections, especially within the aging population. As awareness grows regarding the potential complications associated with shingles, healthcare providers and patients are increasingly prioritizing vaccination as a preventive measure. This growing demand is further supported by advancements in vaccine technology, enhancing both efficacy and safety profiles. Additionally, public health campaigns aimed at educating individuals about the importance of vaccination are contributing to market growth. Consequently, the shingles vaccine market is poised for robust expansion, driven by demographic shifts and an increasing focus on preventive healthcare.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technological Advancement
Regulatory Landscape
Case Studies

Global Shingles Vaccine Market Size by Product & CAGR (2026-2033)

Market Overview
Shingrix
Zostavax
Skyzoster

Global Shingles Vaccine Market Size by Vaccine Type & CAGR (2026-2033)

Market Overview
Recombinant Vaccine
Live Attenuated Vaccine

Global Shingles Vaccine Market Size & CAGR (2026-2033)

North America (Product, Vaccine Type)
- USA
- Canada
Europe (Product, Vaccine Type)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, Vaccine Type)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, Vaccine Type)
- Brazil
- Rest of Latin America
Middle East & Africa (Product, Vaccine Type)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

GlaxoSmithKline (GSK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioNTech SE
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SK bioscience
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GeneOne Life Science
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Curevo Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vaccitech
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jiangsu Recbio Technology Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Changchun BCHT Biotechnology Co.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments